• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

保加利亚的抗菌药物耐药性监测——2003年BulSTAR的概要

Surveillance of antimicrobial resistance in Bulgaria--a synopsis from BulSTAR 2003.

作者信息

Petrov M, Hadjieva N, Kantardjiev T, Velinov Tz, Bachvarova A

机构信息

National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria.

出版信息

Euro Surveill. 2005 Jun;10(6):79-82.

PMID:16077213
Abstract

We introduce Bulgarian Surveillance Tracking Antimicrobial Resistance (BulSTAR) and make the first report on surveillance data for 2003. This longitudinal surveillance programme monitors the isolation and antimicrobial susceptibility of all clinically significant microorganisms isolated from blood cultures, cerebrospinal fluid, upper and lower respiratory tract, urine and wound samples in the participating microbiology laboratories. Twenty eight public, 45 hospital and 6 private laboratories from all 28 counties of the Republic of Bulgaria participated in BulSTAR 2003. The total number of isolates from monitored sources during the surveillance period was 98 929. Seven microorganisms represented 72% of all isolated bacteria in BulSTAR 2003: Escherichia coli, Staphylococcus aureus, Proteus-Providencia-Morganella group, Klebsiella spp., Pseudomonas spp, Streptococcus pneumoniae and Streptococcus pyogenes. Generally the resistance of clinically significant Gram positive and Gram negative bacteria in Bulgaria was estimated to be at a medium level when compared with many other surveillance sources worldwide. A unique 32-year experiment on the population by treating all severe infections with an ampicillin/gentamicin combination resulted in twofold higher levels of resistance to amynoglycosides compared with other countries worldwide. This is due to the extremely conservative treatment schemes used in the former socialist countries, based on national directives and cheap domestic production of gentamicin and ampicillin. The forthcoming introduction of a computer network and improvements in detecting mistakes are expected to increase the sensitivity and the significance of BulSTAR surveillance system - an indispensable tool in the combat against increasing worldwide antibiotic resistance.

摘要

我们引入了保加利亚抗菌药物耐药性监测追踪系统(BulSTAR),并首次报告了2003年的监测数据。这个纵向监测项目对参与的微生物实验室从血培养、脑脊液、上呼吸道和下呼吸道、尿液及伤口样本中分离出的所有具有临床意义的微生物进行分离及药敏监测。保加利亚共和国所有28个县的28家公立、45家医院和6家私立实验室参与了2003年的BulSTAR项目。监测期间从监测来源分离出的菌株总数为98929株。七种微生物占2003年BulSTAR项目中所有分离细菌的72%:大肠杆菌、金黄色葡萄球菌、变形杆菌-普罗威登斯菌-摩根菌属、克雷伯菌属、假单胞菌属、肺炎链球菌和化脓性链球菌。总体而言,与世界上许多其他监测数据来源相比,保加利亚具有临床意义的革兰氏阳性菌和革兰氏阴性菌的耐药性估计处于中等水平。一项对全体人群进行了32年的独特实验,即用氨苄西林/庆大霉素联合治疗所有严重感染,导致对氨基糖苷类药物的耐药水平比世界上其他国家高出两倍。这是由于前社会主义国家采用了极为保守的治疗方案,这些方案基于国家指令以及庆大霉素和氨苄西林的国内廉价生产。预计即将引入的计算机网络以及检测错误方面的改进将提高BulSTAR监测系统的敏感性和重要性,该系统是对抗全球日益增加的抗生素耐药性不可或缺的工具。

相似文献

1
Surveillance of antimicrobial resistance in Bulgaria--a synopsis from BulSTAR 2003.保加利亚的抗菌药物耐药性监测——2003年BulSTAR的概要
Euro Surveill. 2005 Jun;10(6):79-82.
2
Surveillance of antimicrobial resistance in Bulgaria - a synopsis from BulSTAR 2003.保加利亚抗菌药物耐药性监测——2003年BulSTAR报告概要
Euro Surveill. 2005 Jun;10(6):7-8. doi: 10.2807/esm.10.06.00548-en.
3
Frequency of isolation and antimicrobial susceptibility of bacteria isolated from bloodstream infections at Children's Medical Center, Tehran, Iran, 1996-2000.1996 - 2000年伊朗德黑兰儿童医学中心血流感染分离细菌的分离频率及抗菌药敏情况
Int J Antimicrob Agents. 2005 Nov;26(5):373-9. doi: 10.1016/j.ijantimicag.2005.08.004. Epub 2005 Oct 4.
4
Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).新型肽脱甲酰基酶抑制剂LBM415针对呼吸道和皮肤感染病原体的抗菌活性:全球监测报告(2003 - 2004年)
J Antimicrob Chemother. 2006 May;57(5):914-23. doi: 10.1093/jac/dkl093. Epub 2006 Mar 20.
5
Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001).重症监护病房感染患者的病原体发生情况及耐药谱评估:哨兵抗菌监测项目(北美,2001年)报告
Int J Antimicrob Agents. 2004 Aug;24(2):111-8. doi: 10.1016/j.ijantimicag.2003.12.019.
6
Pattern of bacterial infections and antimicrobial susceptibility at the Kenyatta National Hospital, Nairobi, Kenya.肯尼亚内罗毕肯雅塔国家医院的细菌感染模式及抗菌药敏情况。
East Afr Med J. 1997 Mar;74(3):134-7.
7
Patterns of isolation of common gram positive bacterial pathogens and their susceptibilities to antimicrobial agents in Jimma Hospital.吉姆马医院常见革兰氏阳性菌病原体的分离模式及其对抗菌药物的敏感性
Ethiop Med J. 2002 Apr;40(2):115-27.
8
Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).替加环素及对照药物对在欧洲进行的TEST研究(2004 - 2007年)中收集的细菌分离株的抗菌药敏性。
Int J Antimicrob Agents. 2009 Aug;34(2):121-30. doi: 10.1016/j.ijantimicag.2009.02.003. Epub 2009 Apr 1.
9
Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009-2010.亚洲社区获得性呼吸道感染相关细菌病原体的抗菌药物敏感性:2009-2010 年社区获得性呼吸道感染病原体监测(CARTIPS)研究报告。
Int J Antimicrob Agents. 2011 Nov;38(5):376-83. doi: 10.1016/j.ijantimicag.2011.06.015. Epub 2011 Aug 30.
10
Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.针对重症监护病房住院患者的医院内细菌病原体测试替加环素的抗菌活性。
Diagn Microbiol Infect Dis. 2005 Jul;52(3):203-8. doi: 10.1016/j.diagmicrobio.2005.05.002.